Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC Review Ongoing As Teva/Allergan Await Final Approval

Executive Summary

Analysts had been expecting Teva's acquisition of Allergan's generics business to close at the end of June; Teva insists the acquisition is still going to plan.

You may also be interested in...

Mayne Cements Place On US Generics Map

Asset divestments continue in the lead up to Teva's acquisition of Allergan's generics business.

'No Meaningful Change' In Pricing Environment, Teva Says

Teva reported a drop in first quarter revenues that was smaller than expected on better sales from its specialty business. CEO Erez Vigodman claims the deal to acquire Allergan's generics business is on track to close in June and will transform Teva into an "even stronger company."

Allergan's UK Generics Business Up For Sale Under EC Merger Condition

The European Commission has approved the proposed $40.5bn acquisition of the generics business of Allergan (the company formerly known as Actavis) by Teva, subject to a number of significant conditions, including the divestment of the majority of Allergan Generics' business in the UK and Ireland.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts